Clinical trial · Observational
Prognostic Study of HPV Virus Integration in Women With HSIL
Prognostic Study of Different HPV Virus Integration in Women With HSIL
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Human papillomavirus (HPV) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, research has confirmed that carcinogenic HPV type continuous infection leads to a higher incidence of condyloma acuminatum and cervical cancer, while increasing the oropharyngeal cancer, vaginal cancer and other related cancer risk. Based on clinical practice, the purpose of this study was to: 1) identify the correlation between HPV integration and the outcome of disease in HSIL women. 2) To determine the prognostic value of different HPV gene integration status in HSIL women. 3) To clarify the relationship between different HPV gene integration status and diversity of vaginal flora in HSIL women.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
| HSIL, High Grade Squamous Intraepithelial Lesions | High Grade Squamous Intraepithelial Neoplasia | ALIAS | 0.85 |
| Virus Integration | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Follow up | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- HSIL (CIN2,3) women or cervical carcinoma in situ or early invasive carcinoma confirmed by pathology
- description
- In this study, women with pathologically confirmed HSIL(CIN2, 3) or women with cervical carcinoma in situ or early invasive cancer will be included. All participants will have four follow-up visits at enrollment and at months 6, 12, and 24.
- interventionNames
- Other: Follow up
Primary outcomes (16)
- measure
- Cervical cytology testing at baseline
- timeFrame
- Baseline
- description
- All participants were tested for cervical cytology at the time of baseline.
- measure
- Cervical cytology testing at 6-month follow-up
- timeFrame
- 6-month follow-up
- description
- All participants were tested for cervical cytology at 6-month follow-up for all participants.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed HSIL(CIN2, 3) in women or cervical carcinoma in situ or early invasive cancer; * No surgical treatment or conization only; * Obtain informed consent. Exclusion Criteria: * During pregnancy or lactation; * Patients with a history of genital tract cancer; * Previous history of hysterectomy, cervical surgery or pelvic radiotherapy; * Received treatment related to genital tract infection, HPV or other STDs pathogen infection in the past one month; * Use of antibiotics or vaginal microecological improvement products in the past 1 month.
References
Publications (0)
Data not yet available